Safety of Bone marrow-derived Allogeneic Mesenchymal Stem Cells in Parkinson’s disease Patients
Objective: Prove safety and tolerability of allogeneic mesenchymal stem cells (MSC) purified from bone marrow derived from a healthy adult and delivered intravenously in escalated…Pre-diagnosis physical activity habits are associated with age of diagnosis and postural instability in Parkinson’s disease
Objective: To determine if pre-diagnosis exercise and brain-derived neurotrophic factor (BDNF) genotype are predictive of age at diagnosis and severity of balance impairment. Background: Studies…Metabolomic Analysis of Fecal Matter from Parkinsonian Mice
Objective: Assess the metabolic changes in fecal matter in mice treated with an immunomodulatory therapy. Background: The cause of neuronal death in Parkinson’s disease (PD)…K0706, A Potent Orally Bioavailable Brain-Penetrating Selective Inhibitor of cABL Protein Tyrosine Kinase, Exhibits Neuroprotective Activity in Preclinical Models of Parkinson’s Disease
Objective: Preclinical assessment of K0706, a potent c-Abl inhibitor, as a neuroprotective disease modifying agent for the treatment of Parkinson’s disease (PD) related neurodegeneration using…Osteopathic Manipulative Medicine to Improve Balance and Quality of Life in Parkinson Disease
Objective: To examine the effects of Osteopathic Manipulative Medicine (OMM) using a pre-defined protocol for 6 weeks and compare that to a 6-week counseling protocol…Advanced Stage of Parkinson’s Disease: From Identification to Characterization and Disease Burden Assessment Using a Nationwide Database
Objective: To identify and describe PD patients who were prescribed intensified therapy and compare their burden of disease with mild-moderate PD patients. Background: Real-world data…PPMI driven sample size estimation for clinical trials in Parkinson’s disease
Objective: To utilize clinical, imaging and CSF data from the Parkinson’s Progression Markers Initiative (PPMI) to estimate the sample size for disease modification studies in…A Psychometric Analysis of the MDS UPDRS-II and III in Early Parkinson’s disease: Do the Numbers Add Up?
Objective: Our objective was to explore the psychometric evidence for the use of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part II…The Small Molecule Alpha-Synuclein Misfolding Inhibitor, NPT200-11, Produces Multiple Benefits in an Animal Model of Parkinson’s Disease
Objective: To evaluate effects of NPT200-11 on Parkinson’s disease (PD)-relevant outcomes including alpha-synuclein pathology, neurodegenerative markers and motor performance in transgenic mouse models of PD.…A Study to Evaluate the Efficacy of PRX002/RG7935 in Participants With Early Parkinson’s Disease (PASADENA) – Study Design
Objective: To evaluate the efficacy of the anti-alpha-synuclein monoclonal antibody PRX002/RG7935 in a proof-of-concept Phase 2 study in patients with early Parkinson’s disease (PD). Background:…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 19
- Next Page »